[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypovolemic-shock\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypovolemic-shock":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100512743","phase-4-a-study-to-assess-the-safety-and-efficacy-of-centhaquine-in-hypovolemic-shock-patients-100512743",false,"NCT05956418","A Study to Assess the Safety and Efficacy of Centhaquine in Hypovolemic Shock Patients","A Prospective, Multi-centric, Open-labeled, Phase-IV Study to Assess Safety and Efficacy of LYFAQUIN™ (Centhaquine Citrate) as a Resuscitative Agent for Hypovolemic Shock to be Used as an Adjuvant to Standard Treatment of Shock","Inclusion Criteria\n\n• Adult hypovolemic shock patients aged 18 years or older admitted to the emergency room or ICU with systolic blood pressure ≤ 90 mmHg at presentation and continue to receive standard shock treatment. Blood Lactate level indicative of hypovolemic shock (\\>2.0 mmol\u002FL).\n\nExclusion Criteria\n\n* Development of any other terminal illness not associated with hypovolemic shock during the study duration.\n* Patient with altered consciousness not due to hypovolemic shock and comatose patient. • Known pregnancy.\n* Cardiopulmonary resuscitation (CPR) before enrollment.\n* Presence of a do not resuscitate order.\n* Patient is participating in another interventional study.\n* Patients with systemic diseases which were already present before having trauma, such as sepsis, cancer, chronic renal failure, liver failure, decompensated heart failure, or AIDS.","ALL","18 Years",{"count":19,"type":20},400,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","This is a prospective, multi-centric, open-labeled, phase-IV clinical study to evaluate the safety and efficacy of centhaquine citrate (LYFAQUIN™), a first-in-class drug for treating hypovolemic shock, a life-threatening condition caused by severe blood or fluid loss. Centhaquine has been found to be an effective resuscitative agent in rat, rabbit, and swine models of hemorrhagic shock. It has demonstrated the ability to decrease blood lactate levels, increase mean arterial pressure, enhance cardiac output, and reduce mortality rates. The increase in cardiac output during resuscitation is primarily attributed to an augmentation in stroke volume. Centhaquine exerts its effects by acting on the venous α2B-adrenergic receptors, which enhances venous return to the heart. Additionally, it produces arterial dilation by targeting central α2A-adrenergic receptors, thereby reducing sympathetic activity and systemic vascular resistance.",[26],"Hypovolemic Shock",[28,29,30,31,32,33,34],"Shock","Hypovolemia","Hemorrhage","Blood Pressure","Resuscitation","Centhaquine","Adrenergic","RECRUITING","2025-12-26",{"date":38,"type":39},"2025-12-31","ACTUAL",{"date":41,"type":39},"2021-08-13",{"date":43,"type":20},"2026-08",{"name":45,"class":46},"Pharmazz, Inc.","INDUSTRY",17,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100458558","phase-3-a-study-to-assess-safety-and-efficacy-of-centhaquine-as-a-resuscitative-agent-100458558","NCT05251181","A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent","A Multi-Centric, Randomized, Double-Blind, Placebo-controlled, Phase-III Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent to be Used as an Adjuvant to Standard Treatment of Hypovolemic Shock","Inclusion Criteria:\n\nA subject will be eligible for inclusion in the study if he\u002Fshe fulfils the following criteria:\n\n1. Adult males or females aged 18 years or older.\n2. Subjects with hypovolemic shock admitted to the hospital with systolic blood pressure ≤ 90 mm Hg at presentation, Mean Arterial Pressor (MAP) ≤ 65 mm Hg and continue to receive standard treatment of shock (endotracheal intubation; fluid resuscitation and vasopressors). Standard of care to be provided to the subject shall be the one used in that hospital.\n3. Blood lactate level indicative of hypovolemic shock with lactate level more than 2 mmol\u002FL.\n\nExclusion Criteria:\n\nA subject will not be eligible for inclusion in this study if he\u002Fshe meets any of the following exclusion criteria:\n\n1. Subject with illness clinically defined as septic shock (Procalcitonin plasma levels of ≥0.5 ng\u002FmL) or cardiogenic shock or neurogenic shock.\n2. Subject for whom an etiology for hypovolemic shock cannot be determined on initial evaluation.\n3. Hypovolemic shock due to traumatic brain injury, traumatic tamponade, traumatic tension pneumothorax, ventricular wall rupture.\n4. Patient with altered consciousness not due to hypovolemic shock.\n5. Subject with confirmed pregnancy.\n6. Cardiopulmonary resuscitation (CPR) before randomization.\n7. Presence of a do not resuscitate order.\n8. Patient is participating in another interventional study.\n9. Patients with systemic diseases which were already present before having trauma, such as: cancer, chronic renal failure, liver failure, decompensated heart failure or AIDS.",{"count":56,"type":20},430,[58],"PHASE3","This protocol is designed to develop a novel first-in-class treatment for use in critical care and life-threatening condition of hypovolemic shock with unmet need and is of national interest. Shock is a life-threatening condition of circulatory failure. It is a state of cellular and tissue hypoxia due to reduced oxygen delivery and\u002For increased oxygen consumption or inadequate oxygen utilization. Shock most commonly occurs when there is circulatory failure leading to reduced tissue perfusion. There are four types of shock: distributive, cardiogenic, hypovolemic, and obstructive. However, these are not exclusive, and many patients with circulatory failure have a combination of more than one form of shock (multifactorial shock).",[26],"NOT_YET_RECRUITING",{"date":63,"type":39},"2025-12-30",{"date":65,"type":20},"2026-02",{"date":67,"type":20},"2027-10",{"name":45,"class":46},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":80,"conditions":81,"keywords":87,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":103},"100510835","phase-3-early-initiated-vasopressor-therapy-in-the-emergency-department-100510835","NCT05931601","Early Initiated Vasopressor Therapy in the Emergency Department","Early Initiated Vasopressor Therapy vs. Standard Care of Primarily Fluid Therapy in Hypotensive Patients in the Emergency Department - A Pragmatic, Multi-center, Superiority, Randomized Controlled Trial","VASOSHOCK","Inclusion Criteria:\n\n* At least 18 years of age\n* Signs or suspicion of hypotension or shock (of any type such as septic, vasodilatory or hypovolemic not included in the exclusion criteria) defined as:\n\n  1. SBP \\\u003C 100mmHg or MAP \\\u003C 65 mmHg combined with lactate \\> 2.0 mmol\u002FL,\n  2. Physician defined blood pressure for the individual patient combined with a lactate \\> 2.0 mmol\u002FL\n  3. Either SBP \\\u003C 100mmHg or MAP \\\u003C 65mmHg with obvious signs of shock with any lactate level evaluated by either two non-specialist physicians (e.g. registrar medical doctors) or a specialist physician.\n* Received at least 500ml of intravenous fluid before study inclusion (Including prehospital administration) within the first 4 hours of ED arrival.\n* Clinical Frailty Score (CFS) of ≤4. If CFS is ≥5 and the treating physician find the patient suitable for ICU admittance, the participant can be enrolled, if the on-call ICU doctor would accept the patient for ICU admittance. If the treating physician is unsure of ICU eligibility, regardless of CFS score, the patient should be consulted with the ICU consultant before study inclusion.\n\nExclusion Criteria:\n\n* Cardiogenic, anaphylactic, haemorrhagic, or neurogenic shock suspected by the treating physician.\n* Fertile women (\\\u003C60 years of age) with positive urine human gonadotropin (hCG) or plasma-hCG or women breastfeeding.\n* Patient deemed terminally ill or with a severe co-morbid status resulting in non-eligibility for ICU admittance decided by either the treating physician or ICU consultant.\n* Known allergy to noradrenaline.",{"count":78,"type":20},320,[58],"The goal of this pragmatic, multi-center, superiority, randomized clinical trial is to compare early treatment with peripheral (through a vein) infused noradrenaline (a natural hormone that increases blood pressure) with fluid only therapy in patients with hypotensive and shock in the Danish and Swedish Emergency Departments (ED).\n\nThe main questions it aims to answer are:\n\nIf early initiated noradrenaline in non-bleeding hypotensive patients presenting in the ED can\n\n* Improve time to shock control.\n* Reduce the need for ICU admittance.\n* Decrease mortality.\n\nParticipants will be included by the clinical staff and treated urgently with either noradrenaline or usual treatment during their Emergency Department stay.\n\nAfter completion of the treatment in the Emergency Department, patient data will be extracted from the bed-side measurements, electronic health records and national registers.\n\nPatients will be contacted by the research staff 1 year after study inclusion to answer brief questions about their daily physical function and ability to care for themselves.\n\nResearchers will compare with patients receiving fluid therapy only, as this is the usual standard of care in Danish and Swedish Emergency Departments.",[28,82,83,84,85,29,26,86],"Shock, Septic","Hypotension","Hypotension and Shock","Hypotension Symptomatic","Hypovolemic",[88,89,90,91,92],"Peripherally infused noradrenaline","Fluid therapy","Fluid treatment","Non-hemorrhagic shock and hypotension","Emergency Department","2025-06-26",{"date":95,"type":39},"2025-07-01",{"date":97,"type":39},"2023-12-08",{"date":99,"type":20},"2027-01-31",{"name":101,"class":102},"Odense University Hospital","OTHER",8]